/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
These statements concern, and these risks and uncertainties include, among others: competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products") and product candidates being developed by Regenero…
$823.82
+$24.74 (+3.10%)
EOD Sep 1, 2026
24.95% operating margin is above average. ROIC at 8.57%. Note that capital returns lag the margin, the business may be capital-intensive despite high margins.
Revenue growth slowed to 1.0%, essentially flat. Margins also contracted 3.2pp. This is a business that needs a catalyst.
ROIC dropped from 11.87% to 8.57%, capital efficiency is deteriorating. Operating margin contracted 3.2pp YoY, cost discipline may be slipping.
20.4x earnings, 23.2x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$15.53B
▲ +1.0% YoY
Net Income (TTM)
$4.33B
▲ +2.1% YoY
Op. Margin
24.74%
▼ -3.2pp YoY
ROIC
8.81%
▼ -3.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$3.76B
▲ +11.3% YoY
Op. Cash Flow (TTM)
$4.68B
▲ +12.6% YoY
Net Debt
-$5.29B
Net Cash Position
Cash & Equiv.
$7.99B
5Y CAGR: +11.0%
5Y CAGR: +15.3%
Continue Research
SourceComputed from the 10-Q filed 30 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 31 Jul 2026. How this is calculated.
Price from market data, last close as of 1 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 20.4 and a price-to-free-cash-flow of 23.2, Regeneron Pharmaceuticals (REGN) trades above a two-stage DCF intrinsic value of about $664.66 per share, so at $823.82 the stock looks overvalued (19.3% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Regeneron Pharmaceuticals scores 55/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 0.4%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $664.66 per share for REGN, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $498.49. At today's $823.82, that puts the stock about 19.3% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Regeneron Pharmaceuticals scores 55 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 24.7% operating margin and a 8.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Regeneron Pharmaceuticals pays a regular dividend of about $3.57 per share per year (typically in quarterly installments), a yield of roughly 0.4% at the current price. That is a payout ratio of about 8.7% of earnings, so the dividend is amply covered by earnings. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For REGN's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. REGN currently trades above its estimated intrinsic value and scores 55/100 on quality (mixed). It also yields about 0.4%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.